| 前收盘价格 | 22.56 |
| 收盘价格 | 22.48 |
| 成交量 | 652,401 |
| 平均成交量 (3个月) | 737,385 |
| 市值 | 662,822,976 |
| 价格/销量 (P/S) | 6.39 |
| 股市价格/股市净资产 (P/B) | 8.89 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 |
| 营业毛利率 | -159.10% |
| 营业利益率 (TTM) | -22.43% |
| 稀释每股收益 (EPS TTM) | -5.12 |
| 季度收入增长率 (YOY) | 378.80% |
| 总债务/股东权益 (D/E MRQ) | 521.34% |
| 流动比率 (MRQ) | 9.51 |
| 营业现金流 (OCF TTM) | -135.34 M |
| 杠杆自由现金流 (LFCF TTM) | -89.79 M |
| 资产报酬率 (ROA TTM) | -15.35% |
| 股东权益报酬率 (ROE TTM) | -182.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | AnaptysBio, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 5.0 |
| 平均 | 2.50 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.41% |
| 机构持股比例 | 121.67% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ecor1 Capital, Llc | 31 Mar 2025 | 7,880,094 |
| Boxer Capital Management, Llc | 31 Mar 2025 | 1,300,000 |
| Palo Alto Investors Lp | 31 Mar 2025 | 1,020,713 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 90.00 (Guggenheim, 304.86%) | 购买 |
| 中 | 41.00 (84.44%) | |
| 低 | 22.00 (HC Wainwright & Co., -1.04%) | 保留 |
| 平均值 | 48.50 (118.17%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 18.65 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 28 May 2025 | 90.00 (304.86%) | 购买 | 20.90 |
| 06 May 2025 | 54.00 (142.91%) | 购买 | 20.12 | |
| Wedbush | 01 May 2025 | 40.00 (79.94%) | 购买 | 21.70 |
| JP Morgan | 05 Mar 2025 | 42.00 (88.93%) | 购买 | 16.75 |
| HC Wainwright & Co. | 04 Mar 2025 | 22.00 (-1.03%) | 保留 | 15.25 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合